Medexus Pharmaceuticals Inc MEDXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.16
- Day Range
- $1.18–1.22
- 52-Week Range
- $0.84–2.56
- Bid/Ask
- $1.11 / $1.22
- Market Cap
- $28.86 Mil
- Volume/Avg
- 11,281 / 15,241
Key Statistics
- Price/Earnings (Normalized)
- 4.29
- Price/Sales
- 0.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company’s focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 98
- Website
- https://www.medexus.com
Valuation
|
Metric
|
MEDXF
|
|---|---|
Price/Earnings (Normalized) | 4.29 |
Price/Book Value | 0.96 |
Price/Sales | 0.22 |
Price/Cash Flow | 2.05 |
Price/Earnings
MEDXF
Financial Strength
|
Metric
|
MEDXF
|
|---|---|
Quick Ratio | 0.46 |
Current Ratio | 1.11 |
Interest Coverage | 0.94 |
Quick Ratio
MEDXF
Profitability
|
Metric
|
MEDXF
|
|---|---|
Return on Assets (Normalized) | 3.40% |
Return on Equity (Normalized) | 24.35% |
Return on Invested Capital (Normalized) | 18.36% |
Return on Assets
MEDXF
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Qclfcxhdj | Ksdcyx | $78.2 Bil | |
ZTS
| Zoetis Inc Class A | Xzlbvhkv | Xwfb | $78.0 Bil | |
HLN
| Haleon PLC ADR | Ksfhdglw | Mwkn | $37.4 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Rkjfgdbq | Kgsz | $19.1 Bil | |
VTRS
| Viatris Inc | Trngkqqfv | Qnqrt | $12.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Pcwssrpq | Wfsq | $11.8 Bil | |
CTLT
| Catalent Inc | Xxvwymwl | Htxcsn | $9.9 Bil | |
PRGO
| Perrigo Co PLC | Jqttbfj | Dvhpt | $3.8 Bil | |
CURLF
| Curaleaf Holdings Inc | Bnthdjnrk | Chxm | $3.5 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xkgmkbchd | Lwvrm | $3.2 Bil |